<DOC>
	<DOCNO>NCT00003762</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness two regimen docetaxel plus gemcitabine treating patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Docetaxel Gemcitabine Treating Patients With Stage IIIB Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate patient stage IIIB IV nonsmall cell lung cancer different schedule docetaxel gemcitabine therapy . II . Evaluate toxicity treatment patient . III . Describe quality life parameter patient receive combination therapy . IV . Determine survival rate patient . OUTLINE : This randomize study . Patients stratified disease ( stage IIIB v stage IV ) performance status ( 0 vs 1 ) . Patients randomize one two treatment arm ( Arm I close ) . Arm I : Patients receive docetaxel IV 1 hour day 1 follow gemcitabine IV 30 minute day 1 , 8 , 15 . ( close 8/31/1999 ) Arm II : Patients receive docetaxel IV 1 hour gemcitabine IV 30 minute day 1 15 . Arm III : Patients receive docetaxel IV day 1 gemcitabine IV day 1 , 8 , 15 . Patients continue treatment every 28 day maximum 6 course absence unacceptable toxicity disease progression . Patients either stable disease complete/partial response discontinue treatment 4-6 course may eligible NCCTG-97-24-51 . Quality life assess treatment course therapy . Patients follow every 3 month 1 year , every 3 month 5 year . PROJECTED ACCRUAL : A total 19-53 patient accrue study within 6-18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIB/IV nonsmall cell lung cancer eligible first line chemotherapy Measurable disease ( must outside radiation port proof progressive disease ) Metastatic CNS disease allow treat stable least 21 day prior study PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Greater 12 week Hematopoietic : Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Absolute neutrophil count least 1500/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN AST great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : At least 3 month since prior myocardial infarction No uncontrolled congestive heart failure No uncontrolled arrhythmias Other : Not pregnant nursing Fertile patient must use effective contraception Peripheral neuropathy less grade 2 No history hypersensitivity product contain polysorbate 80 No significant medical condition No meningeal carcinomatosis No weight loss great 10 % within past 3 month due disease PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy pelvis , spine , long bone recover No prior radiotherapy least 30 % bone marrow Surgery : Greater 4 week since prior major surgery Other : At least 3 week since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>